Business Context and Reporting Period
Company: Lantern Pharma Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 30, 2020
Reporting Period: Specific event date of December 30, 2020.
Business Overview: Lantern Pharma is a clinical-stage biopharmaceutical company focused on developing cancer treatments, specifically product candidates LP-100 (Irofulven) and LP-184.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing material agreements and does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data. Consequently, specific metrics regarding revenue, margins, debt, and liquidity are not provided in this document.
Material Changes and Agreements
Amendment of AF Chemicals Technology License Agreement (Item 1.01)
- Parties: Lantern Pharma Inc. and AF Chemicals, LLC.
- Agreement: Entered into a Second Addendum to the Technology License Agreement for the exclusive license of global patent rights for LP-100 and LP-184.
- Payment Relief: From December 30, 2020, until January 15, 2025, Lantern Pharma has no obligation to pay annual licensing fees, development diligence extension payments, or patent maintenance fee payments to AF Chemicals.
- New Obligations: Lantern Pharma must make specified payments to AF Chemicals within 10 days of signing and by March 31, 2021.
- Orphan Drug Designation: Lantern Pharma agreed to apply for specified orphan drug designations for LP-184 in the US and EU.
- Recovery Mechanism: The agreement allows Lantern Pharma to recover a portion of initial payments from future sublicense fees or royalty payments made prior to January 15, 2025.
- Term: The agreement continues until the later of the expiration of the last licensed patent or the last orphan drug designation for LP-184.
Califia Pharma Evaluation Agreement (Item 8.01)
- Parties: Lantern Pharma Inc. and Califia Pharma, Inc.
- Agreement: Entered into an Evaluation and Limited Use Agreement.
- Collaboration: Parties will collaborate on in vitro and in vivo testing of novel Califia payloads conjugated to Lantern Pharma targeting entities.
- Strategic Rights: Lantern Pharma secured the right to negotiate exclusive license rights to use LP-184 and related analogs as payloads for antibody or small molecule drug conjugates. Additionally, Lantern Pharma has the right to negotiate non-exclusive license rights to use its targeting entities with Califia's novel payloads and linkers.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights strategic moves to reduce near-term cash outflows (via the AF Chemicals amendment) and to explore novel therapeutic combinations (via the Califia agreement) to improve the therapeutic index of antibody drug conjugates.
Risks and Contingencies:
- Regulatory Risk: Success depends on obtaining orphan drug designations for LP-184 in the US and EU.
- Development Risk: The collaboration with Califia is currently an evaluation phase; future exclusive licensing is subject to negotiation.
- Financial Contingency: While annual fees are waived until 2025, specific payments are due shortly after signing and by March 31, 2021.
Unusual Items: None reported beyond the standard execution of material definitive agreements.
Investor Verification Checklist
- Verify the specific amounts of the "specified payments" due to AF Chemicals within 10 days and by March 31, 2021, as exact figures are not disclosed in this text.
- Confirm the status of the orphan drug designation applications for LP-184 in the US and EU.
- Monitor the outcome of the in vitro and in vivo testing collaboration with Califia Pharma to assess the likelihood of securing exclusive license rights.
- Review subsequent filings for any updates on the negotiation status of the Califia license rights.